Raymond James & Associates’s AbCellera Biologics ABCL Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$32.4K	Sell	12,458 -1,111	-8%	-$3.08K	﹤0.01%	3901
2024 Q2	$40.2K	Sell	13,569 -105	-0.8%	-$397	﹤0.01%	3817
2024 Q1	$61.9K	Buy	13,674 +1,288	+10%	+$6.57K	﹤0.01%	3783
2023 Q4	$70.7K	Sell	12,386 -3,746	-23%	-$17.4K	﹤0.01%	3675
2023 Q3	$74.2K	Sell	16,132 -36,692	-69%	-$223K	﹤0.01%	3643
2023 Q2	$341K	Buy	52,824 +5,691	+12%	+$38.8K	﹤0.01%	3166
2023 Q1	$355K	Buy	47,133 +26,744	+131%	+$243K	﹤0.01%	3135
2022 Q4	$207K	Sell	20,389 -2,076	-9%	-$24K	﹤0.01%	3436
2022 Q3	$222K	Buy	22,465 +4,287	+24%	+$47K	﹤0.01%	3380
2022 Q2	$194K	Buy	18,178 +2,186	+14%	+$18.5K	﹤0.01%	3515
2022 Q1	$156K	Sell	15,992 -56,734	-78%	-$537K	﹤0.01%	3733
2021 Q4	$1.04M	Sell	72,726 -53,625	-42%	-$814K	﹤0.01%	2593
2021 Q3	$2.53M	Buy	126,351 +7,448	+6%	+$132K	﹤0.01%	1933
2021 Q2	$2.62M	Buy	118,903 +46,007	+63%	+$1.27M	﹤0.01%	1908
2021 Q1	$2.48M	Buy	+72,896	New	+$2.9M	﹤0.01%	1869